Mainz Biomed N.V. (MYNZ)
| Previous Close | 0.2387 |
| Open | 0.2387 |
| Bid | 0.2210 x 100 |
| Ask | 0.2243 x 100 |
| Day's Range | 0.2140 - 0.2387 |
| 52 Week Range | 0.1850 - 1.7900 |
| Volume | |
| Avg. Volume | 3,167,267 |
| Market Cap | 14.204M |
| Beta (5Y Monthly) | 0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings Date | Nov 14, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
BenzingaThe Oncology Bet Is Already Paying Off For Pfizer
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs.
GlobeNewswireMainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz B
